HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA safety

This article was originally published in The Rose Sheet

Executive Summary

NTP report on diethanolamine finding "clear carcinogenic activity" is insufficient evidence to support listing under California Prop 65, CTFA Director-Safety and Regulatory Toxicology Linda Loretz maintains at the association's Science Executive Leadership Conference Oct. 29-31 in Washington, D.C. DEA does not meet the standard for causing cancer, Loretz claims. California's Office of Environmental Health Hazard Assessment determined sufficient criteria for listing DEA after reviewing CTFA's April 1999 comments opposing the listing (1"The Rose Sheet" April 26, 1999, p. 11). FDA did not meet its Oct. 1 deadline to complete DEA risk assessment, and will address the issue by the end of fiscal year 2001, Office of Cosmetics & Colors Acting Director Adele Dennis says at CTFA conference
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS008622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel